Compare AbbVie Inc (ABBV) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Teladoc Health Inc — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Teladoc Health Inc trades at $6.83 (market cap $1.29B). The key difference: AbbVie Inc is far larger — about 339.7× Teladoc Health Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| ABBV | TDOC | |
|---|---|---|
Market Cap | $438.19B | $1.29B |
Sector | Health | Health |
52-Week High | $263.58 | $9.72 |
52-Week Low | $197.38 | $4.47 |
Enterprise Value | $502.45B | $1.55B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
TDOC trades at $7.13, up 6.74% in the last session, but remains under pressure after a 28% drop in August 2026 due to a revenue miss and lowered guidance. The stock shows oversold technical signals with RSI near 24, while fundamentals reveal a net loss margin of -7.13% despite a gross margin of 68.97%. Recent news highlights multiple law firm investigations into securities claims, adding to investor uncertainty.
The outlook is cautious; analyst consensus is a hold with a $8.88 price target, but risks include ongoing losses, competitive pressures, and legal scrutiny. Upside depends on execution in integrated care, but near-term volatility is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
